問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of Thoracic Medicine

MacKay Memorial Hospital

Division of Thoracic Medicine

更新時間：2023-09-19

顏嘉德
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

18Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

顏嘉德

List

31Cases

2023-03-27 - 2029-07-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2021-07-27 - 2026-09-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting9Sites

Terminated1Sites

2020-09-15 - 2025-10-08

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2020-04-01 - 2025-11-26

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting4Sites

Terminated1Sites

2015-02-25 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting2Sites

Terminated10Sites

2018-09-01 - 2022-03-31

Phase III

PONENTE: A multicenter, open-label, Phase 3b trial for adult patients with severe eosinophilic leukocyte asthma who are treated with high-dose corticosteroid inhalers, plus long-acting beta 2 agonists and oral corticosteroids for long-term treatment, to evaluate subcutaneously Efficacy and safety of 30 mg injection of Benralizumab for reducing oral corticosteroid dosage

  • Condition/Disease

    Severe eosinophilic leukocyte asthma

  • Test Drug

    Benralizumab

Participate Sites
8Sites

Recruiting8Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬
Taipei Medical University Hospital

Division of Thoracic Medicine

2018-05-01 - 2023-09-30

Phase III

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)

  • Condition/Disease

    TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer

  • Test Drug

    Keytruda injection

Participate Sites
15Sites

Recruiting1Sites

Terminated13Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2017-10-01 - 2023-05-31

Phase III

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)

  • Condition/Disease

    Stage IV, Metastatic Non-small Cell Lung Cancer

  • Test Drug

    Keytruda

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-12-01 - 2019-12-31

Phase III

Multi-center, partially blinded, randomized, 24-week, parallel grouping, non-inferiority, open-label, active controlled trial, comparing the efficacy and safety of QVM149 with salmeterol/fluticasone + tiotropium triple combination therapy for patients with poorly controlled asthma

  • Condition/Disease

    Asthma

  • Test Drug

    QVM149

Participate Sites
9Sites

Terminated7Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

杭良文
China Medical University Hospital-Taipei

未分科

2015-05-01 - 2017-03-25

Phase III

A randomized, double-blind, active drug-controlled, parallel grouping trial, in patients with severe to very severe chronic obstructive pulmonary disease (COPD), using tiotropium as a benchmark to evaluate oral inhaled tiotropium + olodaterol fixed-dose combination once a day The effect of 52-week treatment on the acute onset of COPD. [DYNAGITO]

  • Condition/Disease

    COPD

  • Test Drug

    Tiotropium + Olodaterol fixed dose combination (FDC) inhalation solution- RESPIMATR Inhaler

Participate Sites
15Sites

Terminated13Sites

鍾飲文
Kaohsiung Municipal Gangshan Hospital

未分科

鍾啟禮
Taipei Medical University Hospital

Division of Thoracic Medicine

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB